Ovid Therapeutics (OVID) Cash & Equivalents Growth (1y) (2017 - 2026)
Powered by 
Analysis
Ovid Therapeutics (OVID) Cash & Equivalents Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 9.93% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 1.58% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -14.46% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 14.42% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -40.42% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -57.55% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 84.98% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 103.71% |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | -60.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -60.14% |
| Mar 31, 2026 | 345.04% |
| Dec 31, 2025 | -49.99% |
| Sep 30, 2025 | 37.25% |
| Jun 30, 2025 | -4.31% |
| Mar 31, 2025 | -31.31% |
| Dec 31, 2024 | -2.74% |
| Sep 30, 2024 | -73.85% |
| Jun 30, 2024 | -58.54% |
| Mar 31, 2024 | -51.20% |
| Dec 31, 2023 | -39.73% |
| Sep 30, 2023 | -1.41% |
| Jun 30, 2023 | -1.63% |
| Mar 31, 2023 | -62.60% |
| Dec 31, 2022 | -76.11% |
| Sep 30, 2022 | -71.13% |
| Jun 30, 2022 | -65.69% |
| Mar 31, 2022 | -27.66% |
| Dec 31, 2021 | 160.71% |
| Sep 30, 2021 | 132.31% |